Acorda stock: buy or sell?

ACOR stock price: $2.10 -11.39% At close on January 24th, 2020

Updated on:
January 24th, 2020

2

After boosting an extraordinary 12.66% on Jan 23rd, Acorda Therapeutics closed yesterday at $2.10 and plummed a dreadful -11.39%.

Acorda Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and commercializes therapies for neurological disorders in the United States.

Should I buy Acorda stock?

You can't be a successful trader if you don't follow a methodolgy or system that assist you in choosing companies and the correct market timing. Trading strategies are meant for helping you in the decision process of what stocks to pick and when is the best time to buy them. There are thousands of trading strategies for you to choose, but at Stocks2.com we prefer those that are simple but successful.

None of our preferred buy setups matches with Acorda stock situation right now, hence this is not a suitable entry point.

Buy setupElegible
New all-time highNo
New 52 week highNo
Price crossing up 200d MANo
100d MA crossing up 200d MANo
This doesn't mean ACOR will fall in coming sessions, or it will not rise higher. Simply, it doesn't match our recommended trading systems.

Is Acorda Therapeutics stock a buy?

Everyday, hundreds of stock ratings are published by financial analysts to indicate a particular stock's attractiveness. At Stocks2.com, we detected 7 ratings published for ACOR stock in the last month.

Is ACOR a good stock to buy?
DateAnalyst / BrokerPrevious ratingCurrent rating
2019-8-2Wedbushn/aNeutral
2019-8-2Wedbushn/aNeutral
2019-8-2Stifel Nicolausn/aHold
2019-8-2Cantor Fitzgeraldn/aNeutral
2019-8-14HC WainwrightBuyNeutral
2019-5-7JPMorgan Chase & Co.n/aHold
2019-2-15Cantor Fitzgeraldn/aHold

Acorda stock analysis

Daily outlook

After boosting an extraordinary 12.66% on January/23, Acorda Therapeutics closed yesterday at $2.10 and plummed a dreadful -11.39%.

After boosting an extraordinary 12.66% on January 23rd, Acorda Therapeutics closed yesterday at $2.10 and plummed a dreadful -11.39%. In this session, Acorda Therapeutics stock crossed down the SMA100d line. If you are using SMA100d line as stop loss trigger, double check your position in this stock.

ACOR stock chart (daily)

Weekly outlook

After sliding a bloodcurdling -14.01% in a week last week, Acorda closed this week at $2.10 and inched a decent 1.45%. Late December 2019 ACOR skyrocketed a dazzling 32.06% in just one week.

ACOR shows a long term strength with several rising tops and rising bottoms. It left a new bottom at $1.82 last week. Previous top ($2.78) will play as a resistance in possible new gains. Since last week, when ACOR stock price broke down the 20-weeks moving avarage line, it slid $-0.26 per share (-11.02%).

ACOR stock chart (weekly)

Acorda stock price history

Acorda stock went public on February 10th, 2006 with a price of $6.171. Since then, ACOR stock lost a -66.00%, with a yearly average of -5.10%.

1: Adjusted price after possible price splits or reverse-splits.

Acorda stock historical price chart

ACOR stock reached 52-week highs on January at $17.41, and all-time highs 2015-01-13 with a price of 45.45.

Acorda stock price target is $11.00

How much a stock will be priced tomorrow or next week is quite unpredictable However, financial institutions invest time and resources to provide the most accurated estimations to help investors to make their decisions. The accuracy of these stock price predictions is not very high, and you should not blindly believe and make decisions only based on what this ratings or price target predictions say. For the last month we found 7 price targets for Acorda Therapeutics stock:
ACOR stock price predictions
DateAnalyst / BrokerActionPrevious targetCurrent targetDiff
2019-8-2WedbushReiterates$8.00$7.00-12.5%
2019-8-2WedbushLowers Target$8.00$7.00-12.5%
2019-8-2Stifel NicolausLowers Target$12.00$7.00-41.7%
2019-8-2Cantor FitzgeraldLowers Target$20.00$12.00-40%
2019-8-14HC WainwrightDowngrades$31.00$6.00-80.6%
2019-5-7JPMorgan Chase & Co.Reiteratesn/a$18.00-
2019-2-15Cantor FitzgeraldReiteratesn/a$20.00-
(in average)$15.80$11.00-30.0%
Moving in a range from $20.00 and $6.00, the price prediction for Acorda Therapeutics stock is $11.00. In average, analysts' outlook on ACOR price forecast is negative, downsizing the prediction by a -30.00% from previous estimations.

Financials and fundamental analysis

Earnings date and Earnings per Share

Since February, when Acorda Therapeutics presented its last earnings report, it . Unfortunately, reported EPS is not yet available in our database.
ACOR earnings date and EPS evolution
QuarterReporting dateEstimated EPSActual EPSSurprise
2017-Q1-n/a-0.41n/a
2017-Q2-n/a-0.18n/a
2017-Q32017-10-310.650.43-33.8%
2017-Q42018-02-151.050.61-41.9%
2018-Q12018-05-020.33-0.18n/a
2018-Q22018-08-020.51.29158.0%
2018-Q32018-10-310.020.1400.0%
2018-Q42019-02-14-1.190.41n/a
2019-Q1-n/an/an/a
2019-Q2-n/an/an/a

Annual financial results

Compared to 2017, last anual sales report draw a scary correction of -19.86% to $471.43 million dollars. When comparing 2018 vs 2017, improving that, profit margin (that is, the net income divided by revenues) rocketed a 45.11% to 7.14%.

ACOR annual Sales and Income evolution
YearSalesYoYIncome/(margin)YoY
2013$336 M-$16 M4.9%-
2014$401 M19.34%$18 M4.4%7.49%
2015$493 M22.71%$11 M2.2%-37.43%
2016$520 M5.47%$-34.62 M-6.7%-413.06%
2017$588 M13.22%$-223.36 M-38.0%545.21%
2018$471 M-19.86%$34 M7.1%-115.08%

Quarterly financial results

Acorda Therapeutics posted $69.15 M in revenues for 2018-Q4, a -51.58% decline compared to previous quarter. Reported quarter income marked $9.60 million with a profit margin of 13.88%. Profit margin boosted a 23.62% compared to previous quarter when profit margin was -9.74%. When comparing sales to same quarter last year, Acorda sales marked a hair-raising slide and collapsed a -63.29%. Looking back to recent quarterly results, Acorda Therapeutics posted 2 positive quarters in a row.
ACOR quarterly Sales and Income evolution
QuarterSales1QoQ2Income1/(margin)QoQ2
2017-Q1$119 M-$-19 M-15.8%-
2017-Q2$139 M16.79%$-8 M-5.9%-56.61%
2017-Q3$141 M1.17%$-25 M-17.9%207.26%
2017-Q4$188 M33.55%$-171 M-90.8%578.96%
2018-Q1$106 M-43.65%$-8 M-7.7%-95.21%
2018-Q2$153 M44.40%$46 M30.1%-663.45%
2018-Q3$143 M-6.84%$-14 M-9.7%-130.11%
2018-Q4$69 M-51.58%$10 M13.9%-168.97%

Acorda ownership

When you are planning to invest in shares of a company, it's worth to overview its ownership structure.

Acorda shares owned by insiders (that is, founders, CEO, CTO, main executives or other management staff) currently counts a 1.49% of all shares.

Bearish positions for ACOR stock account 0.00%, no big difference from last month.

The following table compares ownership indicators for other stocks related to Acorda:

ACOR
Market cap$100.9 M
Total shares48.0 M
Float shares43.1 M
  - Institutional holdings (%)118.9%
  - Insider holdings (%)1.5%
Shares in short selling0.0%

Acorda summary

Friday, January 24th, 2020
Open$2.42
Close$2.10
Day range$2.10 - $2.48
Previous close$2.37
Session gain-11.39%
Average true range$0.27
50d mov avg$1.96
100d mov avg$2.37
200d mov avg$5.07
Daily pattern
Weekly pattern lb03a

Acorda performance

Stocks performance is always measured in comparision to the market or competitors and related stocks in the same industry. In the following table, we compare Acorda Therapeutics performance to :
Stock3m6m12m
ACORAcorda Therapeuti...6.60%-69.03%-86.83%

Acorda competitors

Unfortunately, we could not find any public company that could be defined as Acorda competitor. This doesn't mean Acorda does not have any competitor in the market, it's just we could not detected it.